Characteristics and outcomes of patients with BL and HGBL treated with hyper-CVAD-R
| Characteristic N (%) or median [range] . | Total (n = 79) . | BL (n = 54) . | HGBL (n = 25) . | P value . |
|---|---|---|---|---|
| Age at Dx, y | 44 [18-77] | 42 [18-77] | 47 [20-75] | .24 |
| Age ≥60 y | 20 (25) | 12 (22) | 8 (32) | .51 |
| Sex (male) | 51 (65) | 36 (67) | 15 (60) | .75 |
| ECOG PS 0-1 | 52/75 (69) | 35/52 (67) | 17/23 (74) | .76 |
| Stage 4 | 70 (89) | 49 (91) | 21 (84) | .67 |
| BM disease | 58 (73) | 42 (78) | 16 (64) | .31 |
| Extramedullary disease | 36 (46) | 24 (44) | 12 (48) | .96 |
| CNS disease at Dx | 22 (28) | 15 (28) | 7 (28) | 1.00 |
| Positive CSF | 16 (20) | 11 (20) | 5 (20) | |
| Parenchymal disease | 1 (2) | 0 | 1 (4) | |
| Clinical manifestations | 5 (6) | 4 (8) | 1 (4) | |
| LDH ≥ 3 ULN, n (%) | 50 (63) | 38 (70) | 12 (48) | .10 |
| HIV-related | 11 (14) | 9 (17) | 2 (8) | .49 |
| DHL | NA | NA | 7 (28) | |
| IPI | NA | NA | 3.5 [2-5] | |
| CNS-IPI | NA | NA | 3 [1-4] | |
| Treatment outcome, n (%) | ||||
| CR rate | 68/75 (91) | 49/51 (96) | 19/24 (79) | .16 |
| Early death <30 d | 2 (3) | 2 (4) | 0 | .84 |
| Early death <60 d | 5 (6) | 4 (7) | 1 (4) | .93 |
| Relapse | 15/68 (22) | 8/49 (16) | 7/19 (37) | .13 |
| CNS relapse | 4 (5) | 2 (4) | 2 (8) | .43 |
| Isolated CNS relapse | 2 (50) | 1 (50) | 1 (50) | |
| Death | 46 (58) | 31 (57) | 15 (60) | 1.00 |
| Death in CR | 21 (27) | 18 (33) | 3 (12) | |
| Overall survival | .86 | |||
| Median, mo (95% CI) | 71 (18-NR) | 125 (13-NR) | 25 (17-NR) | |
| 5-y, % (95% CI) | 52 (42-64) | 55 (44-70) | 44 (28-68) | |
| Relapse-free survival | .62 | |||
| Median, mo (95% CI) | 127 (54-NR) | 126 (50-NR) | NR (10-NR) | |
| 5-y, % (95% CI) | 58 (48-72) | 59 (47-75) | 57 (39-85) | |
| Cumulative incidence of relapse | ||||
| 5-y, % (95% CI) | 21 (11-30) | 14 (4-24) | 37 (14-59) | .06 |
| Cumulative incidence of CNS relapse | ||||
| 5-y, % (95% CI) | 6 (0 − 12) | 4 (0-10) | 11 (0-25) | .31 |
| Characteristic N (%) or median [range] . | Total (n = 79) . | BL (n = 54) . | HGBL (n = 25) . | P value . |
|---|---|---|---|---|
| Age at Dx, y | 44 [18-77] | 42 [18-77] | 47 [20-75] | .24 |
| Age ≥60 y | 20 (25) | 12 (22) | 8 (32) | .51 |
| Sex (male) | 51 (65) | 36 (67) | 15 (60) | .75 |
| ECOG PS 0-1 | 52/75 (69) | 35/52 (67) | 17/23 (74) | .76 |
| Stage 4 | 70 (89) | 49 (91) | 21 (84) | .67 |
| BM disease | 58 (73) | 42 (78) | 16 (64) | .31 |
| Extramedullary disease | 36 (46) | 24 (44) | 12 (48) | .96 |
| CNS disease at Dx | 22 (28) | 15 (28) | 7 (28) | 1.00 |
| Positive CSF | 16 (20) | 11 (20) | 5 (20) | |
| Parenchymal disease | 1 (2) | 0 | 1 (4) | |
| Clinical manifestations | 5 (6) | 4 (8) | 1 (4) | |
| LDH ≥ 3 ULN, n (%) | 50 (63) | 38 (70) | 12 (48) | .10 |
| HIV-related | 11 (14) | 9 (17) | 2 (8) | .49 |
| DHL | NA | NA | 7 (28) | |
| IPI | NA | NA | 3.5 [2-5] | |
| CNS-IPI | NA | NA | 3 [1-4] | |
| Treatment outcome, n (%) | ||||
| CR rate | 68/75 (91) | 49/51 (96) | 19/24 (79) | .16 |
| Early death <30 d | 2 (3) | 2 (4) | 0 | .84 |
| Early death <60 d | 5 (6) | 4 (7) | 1 (4) | .93 |
| Relapse | 15/68 (22) | 8/49 (16) | 7/19 (37) | .13 |
| CNS relapse | 4 (5) | 2 (4) | 2 (8) | .43 |
| Isolated CNS relapse | 2 (50) | 1 (50) | 1 (50) | |
| Death | 46 (58) | 31 (57) | 15 (60) | 1.00 |
| Death in CR | 21 (27) | 18 (33) | 3 (12) | |
| Overall survival | .86 | |||
| Median, mo (95% CI) | 71 (18-NR) | 125 (13-NR) | 25 (17-NR) | |
| 5-y, % (95% CI) | 52 (42-64) | 55 (44-70) | 44 (28-68) | |
| Relapse-free survival | .62 | |||
| Median, mo (95% CI) | 127 (54-NR) | 126 (50-NR) | NR (10-NR) | |
| 5-y, % (95% CI) | 58 (48-72) | 59 (47-75) | 57 (39-85) | |
| Cumulative incidence of relapse | ||||
| 5-y, % (95% CI) | 21 (11-30) | 14 (4-24) | 37 (14-59) | .06 |
| Cumulative incidence of CNS relapse | ||||
| 5-y, % (95% CI) | 6 (0 − 12) | 4 (0-10) | 11 (0-25) | .31 |
Abbreviations: BM, bone marrow; CI, confidence interval; CNS, central nervous system; CR, complete response; CSF, cerebrospinal fluid; DHL, double-hit lymphoma; Dx, diagnosis; IPI, international prognostic index; LDH, lactate dehydrogenase; mo, months; NA, not available; NR, not reported; PS, performance status; ULN, upper limit normal; y, year.